Enzyre develops an ambulant diagnostic platform that measures up to sixteen coagulation reactions from a small blood sample without laboratory infrastructure. Its first product, Hemophilia EnzyCard, uses the proprietary EnzyPad technology to determine coagulation status in people with hemophilia. The platform is designed for use at home, on the road, or in critical care and can support telemedicine. Reported patient benefits include avoiding crisis situations, empowering patients to optimize treatment, and reducing GP visits. The company raised €12M in a Series A to accelerate development of its proprietary platform and establish manufacturing capabilities. Enzyre is a Nijmegen-based spin-out from Radboud University Medical Center developing Enzypad, a near-patient testing (NPT) device for measuring biomarkers in body fluids. The Enzypad platform uses single-use microfluidic cartridges and requires only a small blood volume, with the ability to measure up to twelve biomarkers simultaneously without laboratory infrastructure. Its first application targets hemophilia, providing real-time coagulation status and automatically sending results to treating physicians via a mobile phone app. Enzyre signed a collaboration with Takeda in December 2019 to develop Enzypad for congenital bleeding disorders, validating the approach. The company positions Enzypad for at-home, on-the-road, and critical-care use and states the technology has broad applicability beyond coagulation testing. Novalis Biotechnology Incubation has joined Enzyre's investor base as part of a recent financing.

Total raised

$14M

Funding rounds

3

Latest round

Series A

Latest activity

Nov 2022